RCUSArcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line […] | IInsider Monkey | |
 Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript CEO Rosen targets casdatifan as $5B to $10B drug with no frontline competition. | ||
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p | MMT Newswires | |
 Arcus Biosciences Q2 Earnings Call Highlights Arcus Biosciences (NYSE:RCUS) outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines. Chief Executive Off | ||
 Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism The fair value estimate for Arcus Biosciences has shifted from US$35.75 to US$38.00, signaling a modest reset in where analysts think the stock could reasonably trade. That move tracks with recent updates that balance enthusiasm around the kidney cancer franchise, especially casdatifan, against questions about how quickly those programs can translate into durable commercial performance. As you read on, you will see how this evolving narrative might shape your view of Arcus Biosciences over... | ||
 Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Arcus Biosciences, Inc.'s Q2 2026 earnings call | ||
 Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations. | ||
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... Summit Therapeutics Inc (SMMT) reports robust financial health and significant progress in clinical trials, despite facing competitive and regulatory challenges. | ||
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development. | ||
 An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge. | ||
IInsider Monkey | ||